Canada Anemia Treatment Market Size, Share, and COVID-19 Impact Analysis, By Disease Type (Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia, and Others), and Canada Anemia Treatment Market Insights Forecasts 2023 - 2033.

Canada Anemia Treatment Market Insights Forecasts to 2033

• The Canada Anemia Treatment Market Size is Growing at 7.12% CAGR from 2023 to 2033.
• The Canada Anemia Treatment Market Size is Expected to Reach a Significant Share by 2033.

The Canada Anemia Treatment Market Size is expected to reach a significant share by 2033, growing at a 7.12% CAGR from 2023 to 2033.     

Market Overview

Canada anemia treatment market is the healthcare sector segment dedicated to the diagnosis, management, and treatment of anemia in the Canadian population. It involves pharmaceutical medications, iron supplements, erythropoiesis-stimulating agents (ESAs), blood transfusions, and sophisticated therapies to treat anemia resulting from iron deficiency, chronic illnesses, kidney disease, and other diseases. It involves hospitals, specialty clinics, retail pharmacies, and research institutions engaged in anemia treatment. The Canadian market for treating anemia is very promising, fueled by growing incidence rates of anemia and improvements in treatment options. The increased awareness and enhanced diagnostic tools. In addition, the emergence of new therapies and government efforts to improve access to healthcare also further contribute to the growth of the market. All these factors together make the environment conducive for stakeholders to invest and innovate in anemia treatment solutions in Canada. In March 2024, Health Canada licensed Ferinject® (ferric carboxymaltose) for intravenous therapy of iron deficiency anemia in adults and children aged one year and older, especially when oral iron is not effective or intolerable. Ferinject is also licensed for the treatment of iron deficiency in adult patients with heart failure to improve exercise tolerance.

Report Coverage

This research report categorizes the market for the Canada anemia treatment market based on various segments and regions forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada anemia treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada anemia treatment market.

Driving Factors

The Canada anemia treatment market is growing strongly, fueled by several important factors. Anemia occurs in about 3% of Canadians, with increased incidence in certain groups; for example, 13% of women aged 12 to 19 and 9% of women aged 20 to 49 have low iron stores, putting them at risk for anemia. The aging population is also a factor in market growth, as anemia is more prevalent in older individuals. Further, the increasing prevalence of chronic conditions like chronic kidney disease (CKD) creates a need for effective anemia management. Growth in treatment approaches, such as the creation of erythropoiesis-stimulating agents and new treatments like hypoxia-inducible factor prolyl hydroxylase inhibitors, drives market growth even further. For instance, Health Canada approved GSK's daprodustat New Drug Submission, an oral HIF-PHI, to treat anemia in CKD patients. All these aspects are responsible for the strong growth of Canada's anemia treatment market.

Restraining Factors

There are numerous restraining factors that affect the Canadian anemia treatment market. High expenses involved in advanced treatments prevent them from reaching most patients. Moreover, the risk of side effects linked to treatments contributes to nonadherence among patients. Lack of knowledge and underdiagnosis are further factors contributing to poor anemia management. In addition, the availability of substitutes poses a further challenge to the market.

Market Segment

• The iron deficiency anemia segment held the greatest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the disease type, the Canada anemia treatment market is divided into iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, aplastic anemia, and others. Among these, the iron deficiency anemia segment held the greatest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is attributed to its high prevalence, increasing awareness, and rising cases among women, children, and the elderly. Growing dietary deficiencies, chronic diseases, and government health initiatives are key drivers fueling its significant CAGR growth over the forecast period.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada Anemia Treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Amgen Inc
• Roche
• Takeda Pharmaceutical Company Limited
• Sanofi
• Novartis AG
• Pharmascience Inc
• Bausch Health Companies Inc
• Teva Canada

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

• This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the Canada anemia treatment market based on the below-mentioned segments:

Canada Anemia Treatment Market, By Disease Type

• Iron Deficiency Anemia
• Chronic Kidney Disease Anemia
• Sickle Cell Anemia
• Aplastic Anemia
• Others